Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia

Antonella Tosti, Massimiliano Pazzaglia, Marcello Soli, Alfredo Rossi, Alfredo Rebora, Laura Atzori, Mauro Barbareschi, Maurizio Benci, Stylianos Voudouris, Gino Antonio Vena

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: To evaluate variations in sexual and erectile function in subjects taking 1 mg of finasteride for androgenetic alopecia by administering the abridged 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire before and during treatment. Design: In a multicenter study, 186 patients with androgenetic alopecia were asked to complete the IIEF-5 regarding the domain of erectile function before (at baseline) and 4 to 6 months after beginning finasteride treatment. The test was self-administered. Setting: The study was conducted in 7 institutional dermatology departments in Italy (Bologna, Rome, Genoa, Cagliari, Milan, Florence, and Bari). Patients: A total of 186 patients with androgenetic alopecia were evaluated before and 4 to 6 months after the initiation of finasteride therapy (1 mg). All patients (age range, 19-43 years; mean age, 28.3 years) were followed up as outpatients. Results: The score on each of the 5 domains of the IIEF-5 did not show any significant change after 4 to 6 months of treatment. Conclusions: Our results support the clinical impression that sexual side effects are actually much less common than reported in clinical trials. The sexual function of all patients remained stable during treatment with 1 mg of finasteride.

Original languageEnglish
Pages (from-to)857-858
Number of pages2
JournalArchives of Dermatology
Volume140
Issue number7
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Finasteride
Alopecia
Therapeutics
Dermatology
Italy
Multicenter Studies
Outpatients
Clinical Trials

ASJC Scopus subject areas

  • Dermatology

Cite this

Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia. / Tosti, Antonella; Pazzaglia, Massimiliano; Soli, Marcello; Rossi, Alfredo; Rebora, Alfredo; Atzori, Laura; Barbareschi, Mauro; Benci, Maurizio; Voudouris, Stylianos; Vena, Gino Antonio.

In: Archives of Dermatology, Vol. 140, No. 7, 01.07.2004, p. 857-858.

Research output: Contribution to journalArticle

Tosti, A, Pazzaglia, M, Soli, M, Rossi, A, Rebora, A, Atzori, L, Barbareschi, M, Benci, M, Voudouris, S & Vena, GA 2004, 'Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia', Archives of Dermatology, vol. 140, no. 7, pp. 857-858. https://doi.org/10.1001/archderm.140.7.857
Tosti, Antonella ; Pazzaglia, Massimiliano ; Soli, Marcello ; Rossi, Alfredo ; Rebora, Alfredo ; Atzori, Laura ; Barbareschi, Mauro ; Benci, Maurizio ; Voudouris, Stylianos ; Vena, Gino Antonio. / Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia. In: Archives of Dermatology. 2004 ; Vol. 140, No. 7. pp. 857-858.
@article{9e7907cb3e9b410eb2b5a344ff94e66e,
title = "Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia",
abstract = "Objective: To evaluate variations in sexual and erectile function in subjects taking 1 mg of finasteride for androgenetic alopecia by administering the abridged 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire before and during treatment. Design: In a multicenter study, 186 patients with androgenetic alopecia were asked to complete the IIEF-5 regarding the domain of erectile function before (at baseline) and 4 to 6 months after beginning finasteride treatment. The test was self-administered. Setting: The study was conducted in 7 institutional dermatology departments in Italy (Bologna, Rome, Genoa, Cagliari, Milan, Florence, and Bari). Patients: A total of 186 patients with androgenetic alopecia were evaluated before and 4 to 6 months after the initiation of finasteride therapy (1 mg). All patients (age range, 19-43 years; mean age, 28.3 years) were followed up as outpatients. Results: The score on each of the 5 domains of the IIEF-5 did not show any significant change after 4 to 6 months of treatment. Conclusions: Our results support the clinical impression that sexual side effects are actually much less common than reported in clinical trials. The sexual function of all patients remained stable during treatment with 1 mg of finasteride.",
author = "Antonella Tosti and Massimiliano Pazzaglia and Marcello Soli and Alfredo Rossi and Alfredo Rebora and Laura Atzori and Mauro Barbareschi and Maurizio Benci and Stylianos Voudouris and Vena, {Gino Antonio}",
year = "2004",
month = "7",
day = "1",
doi = "10.1001/archderm.140.7.857",
language = "English",
volume = "140",
pages = "857--858",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia

AU - Tosti, Antonella

AU - Pazzaglia, Massimiliano

AU - Soli, Marcello

AU - Rossi, Alfredo

AU - Rebora, Alfredo

AU - Atzori, Laura

AU - Barbareschi, Mauro

AU - Benci, Maurizio

AU - Voudouris, Stylianos

AU - Vena, Gino Antonio

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Objective: To evaluate variations in sexual and erectile function in subjects taking 1 mg of finasteride for androgenetic alopecia by administering the abridged 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire before and during treatment. Design: In a multicenter study, 186 patients with androgenetic alopecia were asked to complete the IIEF-5 regarding the domain of erectile function before (at baseline) and 4 to 6 months after beginning finasteride treatment. The test was self-administered. Setting: The study was conducted in 7 institutional dermatology departments in Italy (Bologna, Rome, Genoa, Cagliari, Milan, Florence, and Bari). Patients: A total of 186 patients with androgenetic alopecia were evaluated before and 4 to 6 months after the initiation of finasteride therapy (1 mg). All patients (age range, 19-43 years; mean age, 28.3 years) were followed up as outpatients. Results: The score on each of the 5 domains of the IIEF-5 did not show any significant change after 4 to 6 months of treatment. Conclusions: Our results support the clinical impression that sexual side effects are actually much less common than reported in clinical trials. The sexual function of all patients remained stable during treatment with 1 mg of finasteride.

AB - Objective: To evaluate variations in sexual and erectile function in subjects taking 1 mg of finasteride for androgenetic alopecia by administering the abridged 5-item version of the International Index of Erectile Function (IIEF-5) questionnaire before and during treatment. Design: In a multicenter study, 186 patients with androgenetic alopecia were asked to complete the IIEF-5 regarding the domain of erectile function before (at baseline) and 4 to 6 months after beginning finasteride treatment. The test was self-administered. Setting: The study was conducted in 7 institutional dermatology departments in Italy (Bologna, Rome, Genoa, Cagliari, Milan, Florence, and Bari). Patients: A total of 186 patients with androgenetic alopecia were evaluated before and 4 to 6 months after the initiation of finasteride therapy (1 mg). All patients (age range, 19-43 years; mean age, 28.3 years) were followed up as outpatients. Results: The score on each of the 5 domains of the IIEF-5 did not show any significant change after 4 to 6 months of treatment. Conclusions: Our results support the clinical impression that sexual side effects are actually much less common than reported in clinical trials. The sexual function of all patients remained stable during treatment with 1 mg of finasteride.

UR - http://www.scopus.com/inward/record.url?scp=3142688442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142688442&partnerID=8YFLogxK

U2 - 10.1001/archderm.140.7.857

DO - 10.1001/archderm.140.7.857

M3 - Article

C2 - 15262698

AN - SCOPUS:3142688442

VL - 140

SP - 857

EP - 858

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 7

ER -